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Abstract Single nucleotide polymorphisms (SNPs) in the
KLK3 gene on chromosome 19q13.33 are associated with
serum prostate-speciWc antigen (PSA) levels. Recent
genome wide association studies of prostate cancer have
yielded conXicting results for association of the same SNPs
with prostate cancer risk. Since the KLK3 gene encodes the
PSA protein that forms the basis for a widely used screen-
ing test for prostate cancer, it is critical to fully characterize
genetic variation in this region and assess its relationship
with the risk of prostate cancer. We have conducted a next-
generation sequence analysis in 78 individuals of European
ancestry to characterize common (minor allele frequency,
MAF >1%) genetic variation in a 56 kb region on chro-
mosome 19q13.33 centered on the KLK3 gene
(chr19:56,019,829–56,076,043 bps). We identiWed 555
polymorphic loci in the process including 116 novel SNPs
and 182 novel insertion/deletion polymorphisms (indels).
Based on tagging analysis, 144 loci are necessary to tag the
region at an r2 threshold of 0.8 and MAF of 1% or higher,
while 86 loci are required to tag the region at an r2 thresh-
old of 0.8 and MAF >5%. Our sequence data augments
coverage by 35 and 78% as compared to variants in dbSNP
and HapMap, respectively. We observed six non-synony-
mous amino acid or frame shift changes in the KLK3 gene
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and three changes in each of the neighboring genes, KLK15
and KLK2. Our study has generated a detailed map of
common genetic variation in the genomic region surrounding
the KLK3 gene, which should be useful for Wne-mapping
the association signal as well as determining the contri-
bution of this locus to prostate cancer risk and/or regulation
of PSA expression.
Introduction
Prostate cancer is the most commonly diagnosed non-
cutaneous cancer in men in the US (Jemal et al. 2008).
A widely used test for prostate cancer screening is based on
measuring prostate-speciWc antigen (PSA) protein levels in
serum. However, elevated PSA levels can also be caused by
nonmalignant conditions such as benign prostatic hyperpla-
sia and prostatitis (Punglia et al. 2006). Although the PSA
test has led to the diagnosis of earlier stage prostate can-
cers, the speciWcity and sensitivity of the test is not optimal
for clinical applications (Punglia et al. 2003; Thompson
et al. 2004). Consequently, large randomized screening tri-
als are currently ongoing to assess the beneWts of the PSA
test for prostate cancer screening and mortality rates.
Although interim results have been published (Andriole
et al. 2009; Schroder et al. 2009) the beneWts, if any, of the
PSA test as a diagnostic screening tool for prostate cancer
are still not clear.
A recent genome wide association study (GWAS) of
prostate cancer reported that several single nucleotide poly-
morphisms (SNPs) on chromosome 19q13.33 were associ-
ated with an increased risk of prostate cancer (Eeles et al.
2008b). The most signiWcant SNP, rs2735839, is located
600 bp downstream of the KLK3 gene, which encodes kalli-
krein 3 (hK3), also known as PSA. A notable feature of this
study was that control individuals were selected to have
low PSA levels (<0.5 ng/ml). In a separate GWAS of pros-
tate cancer conducted within the Prostate, Lung, Colorectal,
and Ovarian (PLCO) Cancer Screening Trial, the Wndings
on chromosome 19 were not conWrmed for prostate cancer
susceptibility (Thomas et al. 2008). Further analysis of the
results from the PLCO study indicated an association
between rs2735839 and PSA levels; interestingly, when the
controls were restricted to those with very low PSA levels,
a strong association was observed with prostate cancer risk
(Ahn et al. 2008). In the Wrst study that reported the chro-
mosome 19 association with prostate cancer, the authors
reported evidence for association of rs2735839 and prostate
cancer in additional studies unselected for PSA levels but
the level of signiWcance was substantially less (Eeles et al.
2008a) than in the discovery set with the low PSA controls
(Eeles et al. 2008b). Additional studies have also shown
association between rs2735839 and PSA levels in control
individuals and with less aggressive prostate cancer, but
selection biases for elevated PSA may have played a role
(Kader et al. 2009; Xu et al. 2008). Thus, there is evidence
that the locus on chromosome 19q13.33 is associated with
PSA levels and possibly also prostate cancer.
To conduct follow-up studies in this region of chromo-
some 19q33.13, we generated a map of common SNPs and
insertion/deletion polymorphisms (indels) through a deep
sequencing analysis of a 56 kb region Xanking rs2735839
(chr19:56,019,829–56,076,043 bps; NCBI Build 36.3) in
78 unrelated individuals of European ancestry using a novel
solution-based sequence capture method, combined with
the Roche-454 platform (Rothberg and Leamon 2008). This
region chosen for targeted resequencing is centered on the
KLK3 gene but also includes the neighboring genes KLK15
(centromeric) and KLK2 (telomeric). We identiWed 555
polymorphic loci including 116 novel SNPs and 182 novel
indels. Eleven coding variants were identiWed in the KLK3
gene, including Wve that result in non-synonymous amino
acid changes and one that causes a frameshift in the protein.
Four coding variants were identiWed in the neighboring
KLK15 gene and Wve in the KLK2 gene. This catalog of
common genetic variation establishes a foundation for
comprehensively tagging the region in individuals of
European ancestry for Wne-mapping studies.
Materials and methods
Samples
DNA samples were from 41 prostate cancer cases and 33 con-
trols individuals (total 74) from the National Cancer Insti-
tute’s (NCI) Prostate, Lung, Colorectal, and Ovarian (PLCO)
Cancer Screening Trial (Gohagan et al. 2000). They were
drawn from samples analyzed in the initial scan of the Cancer
Genetics Markers of Susceptibility (CGEMS) Initiative (http:/
/cgems.cancer.gov) (Thomas et al. 2008; Yeager et al. 2007).
Approximately half of the samples from prostate cancer cases
were selected on the basis of high PSA levels (>4 ng/ml,
n = 21) and the other half with low PSA levels (<4 ng/ml,
n = 20). In a similar manner, approximately half of the control
samples came from individuals with low normal PSA levels
(<0.5 ng/ml, n = 17) while the other half were within the high
normal range (2.5–3.9 ng/ml, n =1 6 ) .
DNA samples from 18 individuals in HapMap CEU pedi-
grees were sequenced: 2 three generation CEPH families
(14 individuals from families #1350 and #1444) and two
sets of parents (4 individuals from families #1334 and
#1340). Finally, two trios from YRI pedigrees were
included (6 individuals from families #5 and #16).Hum Genet (2010) 127:91–99 93
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Region sequenced
We sequenced a 56 kb genomic region on chromosome 19
(56,019,829–56,076,043 bps, NCBI Build 36.3) selected
based on the pattern of linkage disequilibrium (LD) around
rs2735839 in the HapMap CEU samples using Haploview
(Barrett et al. 2005). The region was selected to include the
most signiWcant SNP associated with prostate cancer and
PSA levels, rs2735839, and the neighboring region based
on the genetic map (Ahn et al. 2008; Eeles et al. 2008b).
The boundaries were extended to include adjacent blocks
based on the pattern of LD observed in this region using
Phases I and II HapMap Caucasian samples (http://
www.hapmap.org). Finally, we extended the region to fully
include the three kallikrein genes: KLK15,  KLK3 and
KLK2.
Primers, sequence capture and sequencing
Thirteen sets of long-range PCR primers were designed to
cover the 56 kb region targeted. Amplicon size ranged from
3,442 to 5,099 bps and primer sets overlapped, on average,
377 bps with the adjacent amplicon. Primers were designed
using Primer3 (http://frodo.wi.mit.edu) (Rozen and Skaletsky
2000) and then quality checked in silico for uniqueness,
potential sequence paralogy and DNA repeat sequences using
the BLAT feature of the UCSC Genome Browser (http://
genome.ucsc.edu/cgi-bin/hgBlat). Next, NetPrimer (http://
www.premierbiosoft.com/netprimer/index.html) was used
to check for secondary structures and PCR eYciencies.
Primers were ordered from Integrated DNA Technologies
(Coralville, IA). All primers and coordinates are supplied in
Supplemental Table 1.
Biotinylated solution capture probe pools targeting the
regions of interest were generated for sequence capture
(Roche NimbleGen, Madison, WI) (Albert et al. 2007).
Capture was performed in solution in 0.2 ml PCR strip
tubes on a thermal cycler. After »72 h, the capture probe/
sample duplexes were bound to streptavidin magnetic
beads. Captured samples were then ampliWed directly oV
the beads and prepped for sequencing (454 linker ligation).
After long-range PCR, all sequencing protocols were
followed in accordance with standard kits for the 454 GS
FLX system (http://www.454.com/products-solutions/
productlist.asp).
Alignment and detection of polymorphisms
We developed an automated computational pipeline to pro-
cess sequence reads generated by 454 FLX Genome
Sequencers. Whenever applicable, sequence reads from the
same sample were pooled based on barcodes provided by
Roche/454. Quality check (QC) was performed using
vendor-supplied software and sequence reads that passed
QC were aligned to the target genomic region (chr19:56,019,
829–56,076,043 bps) using the MOSAIK software (http://
bioinformatics.bc.edu/marthlab/Mosaik). The resulting assem-
bly was analyzed using a column by column approach and
potential polymorphic sites and most likely genotypes were
called based on a set of heuristic rules. The minimal
sequence coverage depth was set to 20 reads for each nucle-
otide position. In addition, the ratio (r) of forward and
reverse reads was determined. To avoid directional bias, an
optimal range of r was set between 10 and 90%. Homozygous
genotype calls were made when the most frequent allele
was present in at least 85% of the reads. Heterozygous
genotype calls were made when the two most frequent alle-
les were represented in 30–70% of reads. Genotype calls
were not made if the above criteria were not met. Manual
inspections aided by the NextGENe software (http://
www.softgenetics.com) and Consed (http://bozeman.mbt.
washington.edu/consed/consed.html) were performed to
quality assurance (QA) and to resolve ambiguous cases.
Supplemental Table 2 includes Xanking sequences for
polymorphic loci that passed QC and had over 50% com-
pletion rates.
Concordance analysis
Concordance analysis between the re-sequencing data and
CGEMS PLCO scan data was assessed for 74 individuals
(cases and controls). Genotype data for the region
(chr19:56,019,829–56,076,043 bps) was downloaded from
HapMap (http://www.hapmap.org/) and the 1000 Genomes
Project (http://www.1000genomes.org/; imputed geno-
types were not included; Data release: May, 2009) to evalu-
ate genotype concordance between re-sequencing data and
HapMap or 1000 Genomes Project data, respectively.
Twenty-one HapMap samples were used to calculate con-
cordance between the present study and HapMap data. Ten
HapMap samples were used to calculate concordance
between the present study and the 1000 Genomes Project
data. 102 HapMap samples, included in the 1000 Genomes
Project data set were used to calculate concordance
between HapMap and 1000 Genomes Project data. Geno-
type concordance was computed using the GLU software
package (http://code.google.com/p/glu-genetics/).
A two group 2 test of equal proportions (Newcombe
1998) was performed to evaluate the diVerences in minor
allele frequencies (MAFs) for each of 243 SNPs detected
both in this study and the CEU population available in the
1000 Genomes Project data. To correct for multiple testing,
a  q value was calculated using the QVALUE software
package (Storey and Tibshirani 2003) for each test. This
method measures signiWcance in terms of a false discovery
rate (Storey and Tibshirani 2003). Statistical analyses were94 Hum Genet (2010) 127:91–99
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performed using the R statistical software (http://www.
r-project.org/).
Descriptive statistics
Genotype completion, MAF estimations, deviations from
Wtness for Hardy–Weinberg proportion (HWP), pairwise
linkage disequilibrium (LD) and tag SNP selection were
computed using the GLU software package. Inheritance
check analysis was performed on samples from HapMap
families in Haploview (Barrett et al. 2005). Data from 78
unrelated individuals of European ancestry (66 cases/con-
trols and 12 HapMap CEU) was used for SNP tagging
using the GLU software package. LD was visualized in
Haploview (Barrett et al. 2005).
In silico genomic analysis
The presence of highly conserved regions, copy number vari-
ation and predicted regulatory elements was assessed by using
publicly available databases and bioinformatics tools: the
UCSC genome browser (http://genome.ucsc.edu), the Copy
Number Variation database at the Children’s Hospital of
Philadelphia (http://cnv.chop.edu), the Database of Genomic
Variants (http://projects.tcag.ca/variation/) and the VISTA
Enhancer database (http://pipeline.lbl.gov/cgi-bin/gateway2).
Results
Sequence coverage and depth
The average depth and coverage in the genomic region
sequenced (chr19:56,019,829–56,076,043 bps) is shown in
Fig. 1. No gaps were observed in the coverage and the aver-
age depth was 70-fold (range 1- to 136-fold). Low coverage
(<20-fold) was seen in six small regions (cumulative length
1,393 bp) listed in Supplemental Table 3.
Polymorphism discovery and quality control assessment
Genotypes were called for 652 possible SNPs and indels in
74 samples from prostate cancer patients and controls from
the PLCO Cancer Screening Trial (Gohagan et al. 2000), 18
HapMap CEU samples and 6 HapMap YRI samples. Dur-
ing data quality control assessment, samples were excluded
when genotype completion was less than 50% or genotypes
showed discordance with CGEMS PLCO or HapMap geno-
type data. After excluding four samples with 75% or less
genotype concordance with the CGEMS PLCO data, con-
cordance for the remaining samples was 100%. No samples
were excluded based on low concordance with HapMap
data (overall concordance 99.8%). Loci were excluded
based on departures from Hardy–Weinberg equilibrium
(P < 0.001, n = 1) or if they were monomorphic (n =9 2 )  i n
our samples (Supplemental Table 4). No loci were dropped
due to low completion rates. For inheritance check analysis,
only members of the HapMap families were analyzed. No
samples or SNPs were excluded on the basis of Mendelian
errors (overall Mendelian error rate 0%).
A comparison of our dataset with an early build of the
1000 Genomes Project data showed 95.6% concordance
rate, which is not surprising based on the preliminary
nature of the data release. The concordance between Hap-
Map data and 1000 Genomes data was 97.1%. We did not
observe signiWcant diVerences in MAFs for 243 SNPs
detected both in this study and the CEU population avail-
able in the 1000 Genomes Project data set (average diVer-
ence in MAFs = 0.008, range of q values 0.22–1; median
1). The total number of SNPs present in the 1000 Genomes
Project in the targeted region was 365 as compared to 373
in the present study.
The Wnal dataset for individuals of European ancestry
contained genotypes from 78 individuals (66 PLCO and 12
unrelated HapMap samples) and 555 polymorphic loci
(Table 1). These include 116 new SNPs, 182 new indels
and 257 loci previously described in NCBI’s dbSNP data-
base (http://www.ncbi.nlm.nih.gov/projects/SNP/). The lat-
ter number includes 81 HapMap SNPs (http://www.
hapmap.org). The average locus call (completion) rate was
74.4% (range 2.6–100%, median 87.2%) as shown in
Supplemental Fig. 1. MAF estimates were computed for
each locus and were on average 13.2% (range 0.6–50%,
median 6.8%). The number of new SNPs and indels with
MAF >5% was 85. Supplemental Fig. 2 shows the distribu-
tion of MAFs for new and known polymorphisms detected
in the study. Since our indel calling algorithm is still being
reWned, these low-frequency variants should be treated as
preliminary data and require validation. Hence, for the
Fig. 1 Coverage and sequence depth over the 56 kb region sequenced
on chromosome 19q13.33. The horizontal line at 70-fold represents the
average depth and the line at 20-fold represents the cutoV for low cov-
erage. The blue horizontal lines represent primer amplicon
Chr19:56,019,829                       Chr19:56,076,043  
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subsequent analysis we only included loci with completion
rates >50% which included 444 polymorphic loci (112 new
SNPs, 96 new indels and 236 loci previously described in
NCBI’s dbSNP database).
Loci within the KLK15, KLK3 and KLK2 genes
Twenty polymorphic sites were identiWed in the KLK3 gene:
Wve synonymous, Wve non-synonymous, one frameshift
(resulting in a stop codon 23 amino acids downstream of the
site) and nine variants that aVect the 3 untranslated (3UTR)
of diVerent KLK3 isoforms. The proximal promoter contains
three androgen-responsive elements (AREs), ARE I, ARE II
and ARE III, centered at ¡170 bp, ¡394 bp and ¡4,200 bp,
respectively from the transcription start site, that are known to
inXuence  KLK3 expression (Cleutjens et al. 1996;  1997;
Schuur et al. 1996). The presence of two SNPs known to
overlap with functionally validated regulatory elements for the
KLK3 gene was conWrmed (rs266882 in ARE I and rs925013
in an upstream enhancer that contains ARE III) (Cleutjens
et al. 1996; 1997; Cramer et al. 2003; Schuur et al. 1996).
Four coding variants (three non-synonymous and one
synonymous) were observed in the KLK15 gene. Three
additional polymorphic sites were located in the 3 UTR
region of the gene. Five coding variants (1 non-synony-
mous, 2 synonymous and 2 frameshift) were observed in
the KLK2 gene and eight sites were located within the 3
UTR region. Supplemental Table 5 lists polymorphic loci
observed in the three genes and the resulting changes in
amino acid sequences of diVerent KLK isoforms.
Linkage disequilibrium (LD) and tag SNP selection
Based on our sequence data, the map of LD of common
variants (MAF >5%) demonstrates that there are two
blocks of high LD in the telomeric part of the region from
approximately 56,063–56,070 and 56,072–56,075 kb. On
the other hand, the centromeric part of the region sequenced
from  »56,020 to 56,063 kb has low LD (Fig. 2). The
genetic map of this region has been reWned compared to
HapMap data (Supplemental Fig. 3); overall, the current
sequence data corroborates the two HapMap recombination
hotspots located at approximately 56,024–56,026 kb
(recombination rate 54 cM/Mb) and 56,067–56,071 kb
(recombination rate 31 cM/Mb), respectively.
The main SNP associated with prostate cancer from
Eeles et al. (2008b) and with PSA levels from Ahn et al.
(2008), rs2735839, is located at 56,056 kb in an approxi-
mately 37 kb region of relatively low LD. Tagging the
whole region with an r2 threshold of 0.8 and using
rs2735839 as an obligate included marker yielded a total of
144 tag SNPs that are necessary to cover the 357 loci with a
MAF >1% (Table 2). The bin containing rs2735839 con-
tains two additional SNPs located 0.4 kb (rs2569735, MAF
15.6%) and 1.2 kb centromeric (rs1058205, MAF 17.3%)
on chromosome 19. At a MAF of 5% or higher, 86 tags are
needed to cover 227 loci (Table 2). Supplemental Table 6
lists the bin and tag SNP information using thresholds of
MAF ¸1% or 5% and r2 ¸ 0.8. SNPs exhibiting high pair-
wise LD (r2 ¸ 0.8) with rs2735839 are listed in Table 3.
In silico genomic and copy number analysis
The Copy Number Variation project at the Children’s Hos-
pital of Philadelphia (http://cnv.chop.edu) reports heterozy-
gous deletions within the region sequenced. Deletions were
reported in 20/1,320 (1.52%) individuals of European
American ancestry and 4/694 (0.58%) individuals of Afri-
can American ancestry. The CNVs map to 56,022,744–
56,024,482 (1,739 bps) and 56,022,744-56,028,151
(5,408 bps) and are seen in 22 and 2 individuals, respec-
tively (Shaikh et al. 2009). The Database of Genomic Variants
(http://projects.tcag.ca/variation/) reports a loss of small
genomic region about 10 kb telomeric (chr19:56,034,084–
56,034,206 bps) but it is seen in one individual (Levy et al.
2007).
Substantial mammalian conservation was noted for
the exons of all three genes using the UCSC browser
Table 1 Distribution of new and known SNPs and indels that were polymorphic in samples of European ancestry
SNPs single nucleotide polymorphisms, indels insertion and deletion polymorphisms, MAF minor allele frequency
a HapMap phase I, II and III
b Illumina HumanHap610 assay. Note that HapMap and Illumina SNPs are also part of dbSNPs
Category SNPs Indels Total 
variants
Completion
>50%
MAF ¸1% MAF ¸5% All MAF ¸1% MAF ¸5% All
dbSNP 248 211 251 6 3 6 257 236
HapMapa 80 68 81 0 0 0 81 80
Illuminab 28 26 29 0 0 0 29 27
Novel 55 19 116 159 66 182 298 208
All 223 162 367 165 69 188 555 44496 Hum Genet (2010) 127:91–99
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(http://genome.ucsc.edu). Sequences with predicted regula-
tory potential (King et al. 2005) were seen upstream of all
genes, and in some intronic regions, especially in the
KLK15 gene. No experimentally validated or predicted
enhancers are listed in the VISTA browser (http://pipeline.
lbl.gov/cgi-bin/gateway2) for the region (data not shown)
(Couronne et al. 2003).
Discussion
In this study, we have characterized common genetic poly-
morphisms (SNPs and indels) spanning a 56 kb region on
chromosome 19q13.33 in 78 individuals (156 chromo-
somes) of European ancestry by using 454 next-generation
sequencing (Rothberg and Leamon 2008) coupled with a
novel solution-based sequence capture method. This cap-
ture method provides a reliable and less labor intensive
alternative to long-range PCR when sequencing large geno-
mic regions. We discovered 298 new polymorphisms (116
SNPs and 182 indels) and conWrmed 257 previously known
loci in the process and constructed a detailed LD map of the
region. A large fraction (»65%) of the SNPs described here
has also been observed in an early release of the 1000
Genomes Project. Many of the indel polymorphisms
detected are rare and validation is required to conclusively
establish allele frequencies. Our analysis provides a com-
prehensive inventory of common genetic variation in the
region surrounding the KLK3 gene and allows for the selec-
tion of tag SNPs to be used in follow-up studies to thor-
oughly examine the association of genetic polymorphisms
on chromosome 19q13.33 to prostate cancer risk and PSA
levels. At an r2 threshold of 0.8 and MAF of 1% or higher,
144 variants are necessary to tag the region, and at an r2
Fig. 2 Linkage disequilibrium 
(LD) plot across the KLK locus 
on chromosome 19q13.33 as 
measured by r2. Polymorphisms 
in this study with MAF >5% and 
completion rates >50% are 
included. Relative location of 
KLK15, KLK3, KLK2 and 
rs2735839 are shown. 
Coordinates are based on NCBI 
genome build 36.3
Table 2 Tag SNP information, bins and coverage in samples of European ancestry
SNPs single nucleotide polymorphisms, MAF minor allele frequency. Only markers with completion rates >50% were used for tagging. Note that
HapMap and Illumina SNPs are part of dbSNPs
a Number of SNPs and indels used for tagging
b HapMap phase I, II and III
c Illumina HumanHap610 assay
Category na MAF ¸1% and r2 ¸ 0.8 MAF ¸5% and r2 ¸ 0.8
Bins monitored Variants monitored Coverage (%) Bins monitored Variants monitored Coverage (%)
Yes No Yes No Yes No Yes No
dbSNP 236 96 48 233 124 65 76 10 194 33 85
HapMapb 80 42 102 79 278 22 33 53 67 160 30
Illuminac 27 21 123 27 330 8 19 67 25 202 11
Novel 208 57 87 124 233 35 15 71 33 194 15
All 444 144 0 357 0 100 86 0 227 0 100
Table 3 SNPs with r2 > 0.8 with rs2735839
SNPs single nucleotide polymorphisms, MAF minor allele frequency,
Allele count major allele|minor allele
Locus r2 MAF Allele count
rs2569735 1.00 0.156 130|24
rs1058205 0.91 0.173 129|27Hum Genet (2010) 127:91–99 97
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threshold of 0.8 and MAF >5%, 86 loci are required. The
resulting improvement in coverage is an additional 78% as
compared to HapMap SNPs and 35% over variants known
prior to this study (dbSNP).
Chromosome 19q13.33 harbors a cluster of 15 kallikrein
genes tandemly arranged over »300 kb. Three genes that
belong to this family of serine proteases are located within
the region sequenced in this study: KLK15,  KLK3 and
KLK2. The KLK3 gene encodes PSA, a protein that is pro-
duced almost solely by the prostate gland. Small amounts
of PSA are detectable in the bloodstream of healthy men
(Lilja 1985). An increase in serum PSA levels in men with
prostate cancer forms the basis of the PSA test, a widely
used screening tool for prostate cancer. The lack of speci-
Wcity and sensitivity of the test has led to questions about its
usefulness as a screening tool for prostate cancer and two
large prospective randomized trials are currently underway
to directly assess its beneWts: The Prostate, Lung, Colorec-
tal and Ovarian Cancer Screening trial (PLCO) (Andriole
et al.  2009) and the European Randomized Study of
Screening for Prostate Cancer (ERSPC) (Schroder et al.
2009).
The KLK2 and KLK15 genes have also been implicated
in prostate cancer etiology. The KLK2 gene is expressed in
the prostate gland and has been proposed as a potential
marker for prostate cancer. Like PSA, human kallikrein 2
(hK2) levels in the bloodstream are strongly associated
with prostate cancer but do not increase the value of total
PSA measurements for predicting risk of disease (Lilja
et al. 2007). Interestingly, KLK3 and KLK2 share »80%
nucleotide sequence identity across exons, introns and non-
coding regions of the two genes, suggesting a recent dupli-
cation event (Gan et al. 2000). PSA and hK2 also share
»80% amino acid identity (Gan et al. 2000). KLK15 is the
next gene centromeric to KLK3 and shares considerable
similarities to other kallikrein genes. It encodes yet another
member of the kallikrein family, hK15. Expression of the
KLK15 gene appears to be upregulated in a large percent-
age of prostate cancers and is possibly associated with a
higher stage disease (Stephan et al. 2003; Yousef et al.
2001).
Previous association studies with candidate or tag SNPs
have reported a number of SNPs in or near the KLK3 gene
that appear to be associated with prostate cancer, PSA lev-
els or both (Cramer et al. 2003;  2008; Pal et al. 2007).
Results from GWAS and their follow-up studies are con-
Xicting, and it appears that the association to prostate can-
cer may depend on how control individuals were selected.
The SNP most signiWcantly associated with prostate cancer
risk (Eeles et al. 2008b) and PSA levels (Ahn et al. 2008),
rs2735839, lies in a region of relatively low LD. We dis-
covered two markers in high LD (r2 ¸ 0.8) with rs2735839;
thus, these variants are the most likely to be advanced in
laboratory analyses designed to investigate the biological
basis of the association signal(s).
Prostate cancer is the second leading cause of cancer
deaths in the United States (Jemal et al. 2008). It shows
both indolent and aggressive forms and it is diYcult to dis-
tinguish patients that require aggressive therapy and man-
agement from those that should be left to watchful waiting.
Although the beneWts of PSA screening in detecting earlier
stage cancers may be important, this leads to a signiWcant
intervention and unnecessary treatment. Evidence for or
against the eYcacy of PSA screening in reducing morbidity
and mortality due to prostate cancer is eagerly awaited. Our
eVort to comprehensively describe common genetic varia-
tion in the KLK3 locus on chromosome 19q13.33 should
enable a rational approach towards the follow-up analyses
of the role genetic variation plays on PSA levels and pros-
tate cancer risk.
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